• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病皮质类固醇治疗的自然史:一项基于人群的研究。

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

作者信息

Faubion W A, Loftus E V, Harmsen W S, Zinsmeister A R, Sandborn W J

机构信息

Division of Gastroenterology and Hepatology, Section of Biostatistics, Mayo Clinic and Foundation, 200 1st Street, Rochester, MN 55905, USA.

出版信息

Gastroenterology. 2001 Aug;121(2):255-60. doi: 10.1053/gast.2001.26279.

DOI:10.1053/gast.2001.26279
PMID:11487534
Abstract

BACKGROUND & AIMS: The aim of this study was to determine the 1-year outcome after the first course of corticosteroids in an inception cohort of patients with inflammatory bowel disease.

METHODS

All patients in Olmsted County, Minnesota, diagnosed with Crohn's disease (n = 173) or ulcerative colitis (n = 185) from 1970 to 1993 who were treated with systemic corticosteroids were identified (4 denied research authorization). Immediate outcome (30 days) and 1-year outcome after the first course of corticosteroids were determined.

RESULTS

Seventy-four (43%) patients with Crohn's disease and 63 (34%) with ulcerative colitis were treated with corticosteroids. Immediate outcomes for Crohn's disease were complete remission in 43 (58%), partial remission in 19 (26%), and no response in 12 (16%). Immediate outcomes for ulcerative colitis were complete remission in 34 (54%), partial remission in 19 (30%), and no response in 10 (16%). One-year outcomes for Crohn's disease were prolonged response in 24 (32%), corticosteroid dependence in 21 (28%), operation in 28 (38%), and lost to follow-up in 1 (1%). One-year outcomes for ulcerative colitis were prolonged response in 31 (49%), corticosteroid dependence in 14 (22%), and operation in 18 (29%).

CONCLUSIONS

Most patients with Crohn's disease and ulcerative colitis initially respond to corticosteroids. At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation.

摘要

背景与目的

本研究旨在确定炎症性肠病起始队列患者接受首个疗程皮质类固醇治疗后的1年结局。

方法

确定了明尼苏达州奥尔姆斯特德县1970年至1993年间被诊断为克罗恩病(n = 173)或溃疡性结肠炎(n = 185)且接受全身皮质类固醇治疗的所有患者(4人拒绝研究授权)。确定了首个疗程皮质类固醇治疗后的即时结局(30天)和1年结局。

结果

74例(43%)克罗恩病患者和63例(34%)溃疡性结肠炎患者接受了皮质类固醇治疗。克罗恩病的即时结局为完全缓解43例(58%)、部分缓解19例(26%)、无反应12例(16%)。溃疡性结肠炎的即时结局为完全缓解34例(54%)、部分缓解19例(30%)、无反应10例(16%)。克罗恩病的1年结局为反应延长24例(32%)、皮质类固醇依赖21例(28%)、手术28例(38%)、失访1例(1%)。溃疡性结肠炎的1年结局为反应延长31例(49%)、皮质类固醇依赖14例(22%)、手术18例(29%)。

结论

大多数克罗恩病和溃疡性结肠炎患者最初对皮质类固醇有反应。1年后,32%的克罗恩病患者和48%的溃疡性结肠炎患者无需手术且不依赖皮质类固醇。

相似文献

1
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.炎症性肠病皮质类固醇治疗的自然史:一项基于人群的研究。
Gastroenterology. 2001 Aug;121(2):255-60. doi: 10.1053/gast.2001.26279.
2
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis.一项基于人群的关于克罗恩病和溃疡性结肠炎儿科患者中皮质类固醇耐药和依赖频率的研究。
Inflamm Bowel Dis. 2006 Dec;12(12):1093-100. doi: 10.1097/01.mib.0000235835.32176.85.
3
The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.皮质类固醇疗法对炎症性肠病的疗效:对英国一个5年起始队列的分析。
Aliment Pharmacol Ther. 2006 Jul 15;24(2):319-30. doi: 10.1111/j.1365-2036.2006.02974.x.
4
The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease.全肠外营养在炎症性肠病急性发作患者管理中的作用。
J Clin Gastroenterol. 1999 Oct;29(3):270-5. doi: 10.1097/00004836-199910000-00009.
5
Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.溃疡性结肠炎和克罗恩病女性的分娩结局以及抗炎药物治疗的药物流行病学方面
Dan Med Bull. 2011 Dec;58(12):B4360.
6
[Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease].6-巯基嘌呤治疗炎症性肠病的疗效
Rev Esp Enferm Dig. 1995 Nov;87(11):775-80.
7
Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.在一个基于社区的新诊断炎症性肠病患者前瞻性队列中使用皮质类固醇。
Dig Dis Sci. 2016 Jun;61(6):1635-40. doi: 10.1007/s10620-015-4010-4. Epub 2016 Jan 2.
8
Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.与溃疡性结肠炎患儿标准化治疗后早期结局相关的因素(PROTECT):一项多中心发病队列研究。
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):855-868. doi: 10.1016/S2468-1253(17)30252-2. Epub 2017 Sep 20.
9
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.肥胖对炎症性肠病疾病活动和结局的影响:来自瑞士炎症性肠病队列的研究结果。
United European Gastroenterol J. 2020 Dec;8(10):1196-1207. doi: 10.1177/2050640620954556.
10
Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.克罗恩病和溃疡性结肠炎。欧洲一项基于人群的起始队列研究中疾病第一年的发病率、病程及预后
Dan Med J. 2014 Jan;61(1):B4778.

引用本文的文献

1
EPIDEMIOLOGICAL AND CLINICAL PROFILE OF CROHN'S DISEASE IN A BRAZILIAN REFERRAL CENTER IN 30 YEARS OF FOLLOW-UP.一家巴西转诊中心30年随访中克罗恩病的流行病学及临床概况
Arq Gastroenterol. 2025 Sep 5;62:e25032. doi: 10.1590/S0004-2803.24612025-032. eCollection 2025.
2
Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.囊性纤维化与炎症性肠病:肠道生理学与微生物群的相似之处
J Bacteriol. 2025 Sep 18;207(9):e0016725. doi: 10.1128/jb.00167-25. Epub 2025 Aug 18.
3
Short- and longevity outcome of cyclosporin rescue therapy in severe ulcerative colitis refractory to intravenous corticosteroid treatment.
环孢素挽救疗法对静脉注射皮质类固醇治疗无效的重度溃疡性结肠炎的短期和长期疗效。
Therap Adv Gastroenterol. 2025 Aug 8;18:17562848251361054. doi: 10.1177/17562848251361054. eCollection 2025.
4
What is the optimal biological therapy for moderate to severe ulcerative colitis: a systematic review and network meta-analysis.中度至重度溃疡性结肠炎的最佳生物疗法是什么:一项系统评价和网状Meta分析
Front Pharmacol. 2025 Jul 11;16:1602024. doi: 10.3389/fphar.2025.1602024. eCollection 2025.
5
Cardiotonic Steroids as a Potential Novel Approach for Immunomodulation in Inflammatory Bowel Disease.强心甾体类药物作为炎症性肠病免疫调节的一种潜在新方法。
J Clin Med. 2025 Jun 11;14(12):4132. doi: 10.3390/jcm14124132.
6
Effect of ECM nanostructures in decellularized small intestine on differentiation of intestinal epithelial model cells.脱细胞小肠中细胞外基质纳米结构对肠上皮模型细胞分化的影响。
J Artif Organs. 2025 May 22. doi: 10.1007/s10047-025-01509-8.
7
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.瑞莎珠单抗对中度至重度活动性溃疡性结肠炎患者的糖皮质激素节省作用、疗效及安全性
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjaf025.
8
Real-World Experience With Tofacitinib in Steroid-Dependent Patients With Moderate-to-Severe Ulcerative Colitis on Immunomodulators.托法替布在接受免疫调节剂治疗的中度至重度溃疡性结肠炎激素依赖型患者中的真实世界经验
Cureus. 2025 Feb 22;17(2):e79456. doi: 10.7759/cureus.79456. eCollection 2025 Feb.
9
Probiotic nanocomposite materials with excellent resistance, inflammatory targeting, and multiple efficacies for enhanced treatment of colitis in mice.具有优异抗性、炎症靶向性和多种功效的益生菌纳米复合材料,用于增强小鼠结肠炎的治疗效果。
J Nanobiotechnology. 2025 Mar 8;23(1):188. doi: 10.1186/s12951-025-03240-1.
10
Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption.克罗恩病中肠道药物代谢酶和转运体的变异性及其对口服药物吸收的潜在影响。
Br J Clin Pharmacol. 2025 Jul;91(7):2028-2044. doi: 10.1002/bcp.70019. Epub 2025 Mar 4.